Israel-Based Clearmind Medicine Inc. CEO Discusses the Potential of Psychedelics for Addiction Treatment in Audio Interview with SmallCapVoice.com

AUSTIN, TX / ACCESSWIRE / January 4, 2023 / SmallCapVoice.com Inc. ("SCV") announces the availability of a new interview with Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine Inc. (NASDAQ:CMND)(CSE:CMND)(FWB:CWY), to discuss the biotech company's use of non-hallucinogenic psychedelic compounds to treat physical and mental health, including addiction.

The full interview can be heard at: https://www.smallcapvoice.com/nasdaq-cmnd-audio-interview-with-smallcapvoice-com/ .

Clearmind's intellectual portfolio consists of seven patent families. Its lead candidate, CMND-100, is derived from 5-methoxy-2-aminoindane (MEAI), a psychoactive molecule that exerts a euphoric alcohol-like experience and a reduced desire to consume alcohol. CMND-100 is headed for clinical trials in early 2023 as a potential treatment for alcohol-use disorder (AUD), and Clearmind is also exploring the use of its MEAI-based compound to treat cocaine addiction and depression.

Earlier this month, Clearmind was granted a patent from the United States Patent and Trademark Office (USPTO) for the use of its proprietary MEAI as an alcoholic beverage substitute. Speaking with SCV's Stuart Smith, Dr. Zuloff-Shani explains the global need for such treatment.

"The number of alcoholics is striking," she says. "We're talking about millions around the world. Alcohol consumption contributes to 3 million deaths each year globally. It is the third leading, preventable cause of death in the U.S. and the yearly cost is enormous - around $200-$250 billion and that's in 2010."

Despite the statistics, Dr. Zuloff-Shani says that existing treatment options in this largely underserved market are largely ineffective. "You would think that a huge problem probably has a lot of treatments to offer," she explains. "But it's just the opposite. Since 1950, only three treatments were approved by the FDA. I cannot say that any of them are very effective or have no adverse events associated with it."

In pre-clinical studies, however, MEAI has demonstrated a promising efficacy in individuals who struggle with alcohol, helping to break the addiction cycle. Clearmind's interest in the component came from the testimonials of people who purchased it to better manage their alcohol consumption.

As Dr. Zuloff-Shani explains in the interview, Clearmind paid attention to those experiences and the company selling the MEAI component online. Convinced of MEIA's potential as a safe treatment option, it then acquired certain worldwide patents of MEAI used that information as an entry point for its own compound. Now, Clearmind is working on an Investigational New Drug (IND) application with the FDA as it advances toward clinical studies of MEAI next year.

"Usually when you develop a compound, you start from the other direction. You have an idea. You develop a compound and then you go to petri dishes and to animals, and finally you hope that you will have the same signal as, as you had in animals and in petri dishes in humans," explains Dr. Zuloff-Shani. "Here, we are just doing the reverse process. We believe [MEAI] has the potential to be effective and safe … but of course this will be determined by the FDA, and this is why we decided that we want to do it in a safe place and take the FDA route."

Smith then shifts the conversation toward Clearmind's most recent developments and the strength of its management team, staff and scientific advisory board. Dr. Zuloff-Shani describes the structure of Clearmind's operations and how it benefits corporate objectives and overhead.

"We have a very impressive staff in the company," says Dr. Zuloff-Shani, who is well-versed in navigating regulatory pathways through her more than 20 years of experience in the biotech and pharmaceutical industries. "We don't have a lot of people, and this is by choice. We prefer to work in outsourcing because that enables us to manage our expenses better. On the other hand, it allows us to really collaborate in every field that we are dealing with."

The interview concludes with what Clearmind expects to achieve in the New Year and how it plans to overcome the challenges associated with advancing toward clinical trials.

"The most important milestone we need to hit on 2023 is this IND application … this is really a major event in any company. We expect to have two clinical sites: one in the United States and one in Israel. So, it will be two applications to do different regulatory borders, asking the permission to start clinical trials, and then of course to start a clinical trial," says Dr. Zuloff-Shani. "And then I hope that you interview me in December next year and I will tell you that we are now at the last stages of the study or reaching completion of the study."

To hear the full interview with SCV, visit: https://www.smallcapvoice.com/nasdaq-cmnd-audio-interview-with-smallcapvoice-com/ .

About Clearmind Medicine Inc.

Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

The Company's intellectual portfolio currently consists of seven patent families. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND", the Canadian Securities Exchange under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol "CWY."

About SmallCapVoice.com

SmallCapVoice.com, Inc. is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies, small cap and micro-cap stocks build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, podcasts, as well as its clients' financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks in which they are interested. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTCMarkets. To learn more about SmallCapVoice.com and its services, please visit https://www.smallcapvoice.com/small-cap-stock-otc-investor-relations-financial-public-relations/.

Socialize with SmallCapVoice and their clients at

Facebook: https://www.facebook.com/SmallCapVoice/
Twitter: https://twitter.com/smallcapvoice
Instagram: https://www.instagram.com/smallcapvoice/

Forward Looking Statements:

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its IND application and conducting clinical trials. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the Securities and Exchange Commission ("SEC"), including, but not limited to, the risks detailed in the Company's final prospectus (registration No. 333-265900) filed with the SEC on November 16, 2022. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.

Contact Information:

Investor Relations:
Email: Invest@ClearmindMedicine.com
Telephone: (604) 260-1566
General Inquiries:
Info@ClearmindMedicine.com
www.ClearmindMedicine.com

SmallCapVoice.com

Stuart T. Smith
512-267-2430
Info@SmallCapVoice.com

SOURCE: SmallCapVoice.com